News blog
Alltracel Pharmaceuticals
- BY: Andrew Hore |
- POSTED: 21/01/2008 |
- COMMENTS: Add yours
Wound and skin care products developer Alltracel Pharmaceuticals says it is talking to a possible bidder.
It is described as a “very preliminary approach”. The shares rose 0.625p to 9.875p.
In a trading statement, Alltracel said that the integration of oral care and sports bandage supplier Synpart had progressed well and it is expected to a key factor for revenue growth in 2008.
In July 2007 the company’s healthcare technology business, Nanopeutics, signed a licensing agreement with HemCon Medical Technologies which could lead to products being launched in 2008. It also has a technology development agreement with wound care company ConvaTec. If the agreement progresses as planned it could lead to an exclusive royalty bearing license and supply agreement between the two companies.
Alltracel has formed a UK-based contract research joint venture with Canadian research organisation Venn Life Sciences.
The 2007 results are due to be reported in early April.
© 2007 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- 2.4mNumber of messages posted on SocialGo networks
- $38mCost savings generated by ideas from WalMart staff over a two month period
- 19.4m
Number of people passing through Johannesburg Airport in 2007
- News Blog
- All micro news
Geong International Ltd
Geong International Ltd says that it considered a Hong Kong listing but it has no intention of moving ahead with this.
1PM
Asset finance provider 1PM has secured £700,000 of additional funding from two separate loans.
African Land
African Land is the latest agricultural business planning to join Aim.
Fiske
Broker Fiske says its second quarter trading was disappointing and it expects markets to continue to be lacklustre.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|